In contrast, more than 46% of eligible patients treated with TKIs—primarily imatinib (a BCR-ABLi) and pazopanib (a VEGFi)—at the Mayo Clinic in the U.S. were mainly diagnosed with renal cell carcinoma (RCC) [7]. Here, BCR is linked to hereditary clear cell renal cell carcinoma.